BIO RAD LABORATORIES INC. – LIQUICHEK TUMOR REGEANTS

Place of Performance: National Institutes of Health Clinical Center Bethesda, MD 20892 POTS: 26-005107 Description This notice is issued for informational purposes only and does not constitute a request for quotations. A solicitation will not be issued, and quotations will not be requested. The National Institutes of Health (NIH), Clinical Center, intends to award a sole source firm-fixed-price contract to Bio-Rad Laboratories for the procurement of Liquichek Tumor Regeants. The requirement consists of testing controls for cardiac, cancer and infectious disease markers for Liquichek Tumor Regeants, which provide consistent, high-quality results for clinical center patients within the Department of Laboratory Medicine (DLM) Immunoassay laboratory. Background The Department of Laboratory Medicine (DLM) Immunoassay laboratory currently provides services for 35 protocols across several Institutes, and they all require highly accurate and rapid results. In addition, some research protocols extend over several years, it is very important for laboratory values to remain consistent over time through the same testing methodologies and similar instrumentation. Rationale: Bio-Rad Laboratories is the sole manufacturer of Liquichek Tumor Regeants. Substitution is not permissible without revalidation and regulatory approval, which could delay treatment and pose risks to patient care Authority This acquisition is being conducted in accordance with: FAR 13.106-1(b)(1) – Soliciting from a Single Source Under this authority, the Contracting Officer may solicit from a single source when it is determined that only one source is reasonably available to meet the Government’s requirements. Acquisitions conducted under FAR Part 13 – Simplified Acquisition Procedures are exempt from the competition requirements of FAR Part 6. Responses This is not a request for quotations. However, interested parties may submit a capability statement demonstrating their ability to meet the Government’s requirement. Responses must include: Company name and address Technical capability Proof of OEM authorization Relevant past performance The Government will evaluate capability statements received in response to this notice. The determination not to compete this requirement is solely within the discretion of the Government. Submission Instructions Responses referencing POTS: 26-005107 must be submitted electronically no later than May 24, 2026, at 8:00 AM EST to: Gregory Noland Hospital and Laboratory Support Division Office of Acquisitions and Logistics Management National Institutes of Health Email: gregory.noland@nih.gov